Retatrutide

Retatrutide is a synthetic 39-amino-acid peptide modelled on the GIP scaffold with substitutions enabling balanced agonism at three receptors. Adding glucagon-receptor activity increases resting energy expenditure and hepatic lipid oxidation, on top of the appetite-suppressing GLP-1/GIP effects.

Half-life: ≈ 6 days

• Mean 24.2% reduction in body weight at 48 weeks with 12 mg (Jastreboff 2023)
• Robust improvement of hepatic steatosis on MRI-PDFF
• Glycemic control in type 2 diabetes comparable to or beyond dual agonists
• Weekly dosing schedule

Phase-2 protocols escalated from 2 mg weekly to a maintenance of 8 or 12 mg over 12-24 weeks. No approved retail dosing exists; treat as investigational.

Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.

• Retatrutide phase-2 obesity trial

  New England Journal of Medicine · 2023

  338 adults randomised; 12 mg weekly produced a 24.2% mean body-weight reduction at week 48.

• GI adverse events more prominent than with dual agonists at equipotent doses
• Modest dose-dependent increases in heart rate observed
• Long-term cardiovascular safety pending phase-3 outcomes

For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.